Trials / Completed
CompletedNCT04332627
Comparison of QoR-15 in Laparoscopic Cholecystectomy: Sugammadex vs. Neostigmine
Comparison of Quality of Recovery Score (QoR-15) According to Neuromuscular Blocking Reversal Agent in Laparoscopic Cholecystectomy: Sugammadex vs. Neostigmine
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 77 (actual)
- Sponsor
- Seoul National University Bundang Hospital · Academic / Other
- Sex
- All
- Age
- 20 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The quality of recovery in patients who were reversed neuromuscular blockade by using Sumamadex and Neostigmine in laparoscopic cholecystectomy was compared through the QoR(Quality of Recovery)-15 questionnaire.
Detailed description
Quality of Recovery questionnaire includes five details (Emotional status, Physical comfort, Physiological support, Physical independece, Pain), and is a proven method of reliability, consistency and validity for evaluating recovery from surgery and anesthesia. After laparoscopic cholecystectomy, patients experience various discomforts such as pain, nausea, vomiting, and placebo due to general anesthesia. Neostigmine has side effects such as crampy abdominal pain, nausea and vomiting. In addition, residual neuromuscular blockade was higher in neostigmine compared with sugammadex. Although sugammadex expected to improve patient's recovery, it is still controversial that sugammadex contributes to clinically meaningfull difference compared with neostigmine. Therefore, the aim of our study is comparison of quality of recovery through QoR-15 questionnaire in patients who were reversed neuromuscular blockade by using sugammadex and neostigmine in laparoscopic cholecystectomy.
Conditions
- Neuromuscular Blockade Reversal Agent
- Sugammadex
- Neostigmine
- Quality of Recovery
- Laparoscopic Cholecystectomy
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sugammadex | sugammadex 2mg/kg or 4mg/kg according to Train-of-four count (TOF 0 : 4mg/kg, TOF 1-4 : 2mg/kg) |
| DRUG | Neostigmine | with glycopyrrolate 0.4mg, neostigmine 0.02mg/kg or 0.04mg/kg or 0.05mg/kg according to Train-of-four count (TOF 0 : wait until TOF 2, TOF2-3: 0.05mg/kg, TOF4: 0.04mg/kg) |
Timeline
- Start date
- 2020-02-24
- Primary completion
- 2020-05-21
- Completion
- 2020-05-21
- First posted
- 2020-04-02
- Last updated
- 2020-12-24
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04332627. Inclusion in this directory is not an endorsement.